KR20180050744A - 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도 - Google Patents
신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도 Download PDFInfo
- Publication number
- KR20180050744A KR20180050744A KR1020187010231A KR20187010231A KR20180050744A KR 20180050744 A KR20180050744 A KR 20180050744A KR 1020187010231 A KR1020187010231 A KR 1020187010231A KR 20187010231 A KR20187010231 A KR 20187010231A KR 20180050744 A KR20180050744 A KR 20180050744A
- Authority
- KR
- South Korea
- Prior art keywords
- spis
- eqlsn
- ykqye
- eplt
- peptide
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562219728P | 2015-09-17 | 2015-09-17 | |
US62/219,728 | 2015-09-17 | ||
PCT/EP2016/071794 WO2017046227A2 (en) | 2015-09-17 | 2016-09-15 | Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof. |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20180050744A true KR20180050744A (ko) | 2018-05-23 |
Family
ID=56936411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020187010231A KR20180050744A (ko) | 2015-09-17 | 2016-09-15 | 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도 |
Country Status (17)
Country | Link |
---|---|
US (1) | US20190290729A1 (da) |
EP (3) | EP3349776B1 (da) |
JP (2) | JP7236134B2 (da) |
KR (1) | KR20180050744A (da) |
CN (1) | CN109715190A (da) |
AU (1) | AU2016323407A1 (da) |
CA (1) | CA2998297A1 (da) |
DK (1) | DK3349776T3 (da) |
ES (1) | ES2862103T3 (da) |
HR (1) | HRP20210441T1 (da) |
HU (1) | HUE053697T2 (da) |
IL (2) | IL299622A (da) |
LT (1) | LT3349776T (da) |
PL (1) | PL3349776T3 (da) |
SG (1) | SG10201913366QA (da) |
SI (1) | SI3349776T1 (da) |
WO (1) | WO2017046227A2 (da) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109311956A (zh) | 2015-08-25 | 2019-02-05 | 伊斯迪德股份公司 | 诱导组织形成的化合物及其应用 |
CA2998455A1 (en) * | 2015-09-17 | 2017-03-23 | Histide Ag | Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof |
JP2020529472A (ja) | 2017-07-28 | 2020-10-08 | サークル ファーマ,インコーポレイティド | ペプチド化合物の環化放出関連する出願の相互参照 |
CN116204770B (zh) * | 2022-12-12 | 2023-10-13 | 中国公路工程咨询集团有限公司 | 一种用于桥梁健康监测数据异常检测的训练方法及装置 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US20030185792A1 (en) * | 1996-01-22 | 2003-10-02 | Curis, Inc. | Morphogen analogs of bone morphogenic proteins |
US5846536A (en) * | 1996-10-04 | 1998-12-08 | The Regents Of The University Of California | Restoration of normal phenotype in cancer cells |
DE19748688C2 (de) * | 1997-04-22 | 2001-09-06 | Hans Georg Graeber | Membransystem zur gesteuerten Geweberegeneration bei Erkrankungen des Zahnhalteapparates |
US20040023322A1 (en) * | 2002-08-01 | 2004-02-05 | Goodheart Clyde R. | Method of producing non-recombinant BMP-2 and use thereof |
WO2005030933A2 (en) * | 2003-09-24 | 2005-04-07 | Genera Doo | Bone morphogenetic protein (bmp)-7 based diagnosis and treatment of cancer |
US7528105B1 (en) * | 2004-02-10 | 2009-05-05 | Biosurface Engineering Technologies | Heterodimeric chain synthetic heparin-binding growth factor analogs |
CA2595902C (en) * | 2005-01-24 | 2017-08-22 | Pepscan Systems B.V. | Binding compounds, immunogenic compounds and peptidomimetics of the beta-3 hairpin loop of cystine-knot growth factors |
ES2710601T3 (es) * | 2005-07-19 | 2019-04-26 | Stemgen S P A | Inhibición del potencial tumorigénico de células madre tumorales por LIF |
WO2007114851A1 (en) * | 2006-04-04 | 2007-10-11 | The Board Of Trustees Of The University Of Illinois | Methods and compositions to induce cell death of invasive tumors |
US7998740B2 (en) * | 2006-07-18 | 2011-08-16 | Robert Sackstein | Cytokine induction of selectin ligands on cells |
GB0615129D0 (en) * | 2006-07-29 | 2006-09-06 | Univ Cardiff | Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies |
KR100894265B1 (ko) * | 2007-06-05 | 2009-04-21 | 재단법인서울대학교산학협력재단 | 골형성 촉진 펩타이드를 함유하는 주입형 골재생재 |
CA2694644A1 (en) * | 2007-07-27 | 2009-02-05 | Vanitha Ramakrishnan | Pharmaceutical combinations |
CN103561761A (zh) * | 2011-03-23 | 2014-02-05 | 加利福尼亚大学董事会 | 用于使用抗-整合素改善抗血管生成疗法的方法和组合物 |
SG11201508681QA (en) * | 2013-05-06 | 2015-11-27 | Scholar Rock Inc | Compositions and methods for growth factor modulation |
-
2016
- 2016-09-15 CA CA2998297A patent/CA2998297A1/en not_active Abandoned
- 2016-09-15 EP EP16766294.9A patent/EP3349776B1/en active Active
- 2016-09-15 EP EP20215344.1A patent/EP3875102A1/en active Pending
- 2016-09-15 US US15/760,980 patent/US20190290729A1/en not_active Abandoned
- 2016-09-15 LT LTEP16766294.9T patent/LT3349776T/lt unknown
- 2016-09-15 AU AU2016323407A patent/AU2016323407A1/en not_active Abandoned
- 2016-09-15 ES ES16766294T patent/ES2862103T3/es active Active
- 2016-09-15 EP EP20214632.0A patent/EP3906932A3/en active Pending
- 2016-09-15 KR KR1020187010231A patent/KR20180050744A/ko not_active Application Discontinuation
- 2016-09-15 IL IL299622A patent/IL299622A/en unknown
- 2016-09-15 HU HUE16766294A patent/HUE053697T2/hu unknown
- 2016-09-15 DK DK16766294.9T patent/DK3349776T3/da active
- 2016-09-15 SI SI201631119T patent/SI3349776T1/sl unknown
- 2016-09-15 CN CN201680067441.0A patent/CN109715190A/zh active Pending
- 2016-09-15 SG SG10201913366QA patent/SG10201913366QA/en unknown
- 2016-09-15 PL PL16766294T patent/PL3349776T3/pl unknown
- 2016-09-15 JP JP2018514821A patent/JP7236134B2/ja active Active
- 2016-09-15 WO PCT/EP2016/071794 patent/WO2017046227A2/en active Application Filing
-
2018
- 2018-03-14 IL IL258131A patent/IL258131B2/en unknown
-
2021
- 2021-03-16 HR HRP20210441TT patent/HRP20210441T1/hr unknown
-
2022
- 2022-12-23 JP JP2022206775A patent/JP2023027372A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2016323407A1 (en) | 2018-04-19 |
ES2862103T3 (es) | 2021-10-07 |
LT3349776T (lt) | 2021-03-25 |
SI3349776T1 (sl) | 2021-04-30 |
PL3349776T3 (pl) | 2021-08-02 |
EP3349776A2 (en) | 2018-07-25 |
IL258131A (en) | 2018-05-31 |
HRP20210441T1 (hr) | 2021-04-30 |
WO2017046227A2 (en) | 2017-03-23 |
HUE053697T2 (hu) | 2021-07-28 |
JP2018536623A (ja) | 2018-12-13 |
EP3906932A3 (en) | 2021-12-01 |
IL258131B2 (en) | 2023-06-01 |
SG10201913366QA (en) | 2020-02-27 |
WO2017046227A3 (en) | 2017-06-29 |
IL299622A (en) | 2023-03-01 |
JP7236134B2 (ja) | 2023-03-09 |
CA2998297A1 (en) | 2017-03-23 |
EP3875102A1 (en) | 2021-09-08 |
EP3349776B1 (en) | 2020-12-30 |
JP2023027372A (ja) | 2023-03-01 |
US20190290729A1 (en) | 2019-09-26 |
EP3906932A2 (en) | 2021-11-10 |
DK3349776T3 (da) | 2021-03-22 |
CN109715190A (zh) | 2019-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6890835B2 (ja) | 腫瘍細胞を非腫瘍細胞に変換するための医薬的連合体及びその使用 | |
JP7261499B2 (ja) | 腫瘍細胞を非腫瘍細胞に変換するための医薬的連合体及びその使用 | |
JP2023027372A (ja) | 腫瘍細胞を非腫瘍細胞に変換するための医薬的連合体及びその使用 | |
EP3349778B1 (en) | Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof | |
WO2017046229A1 (en) | Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |